UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015650
Receipt number R000018195
Scientific Title Effects of dexmedetomidine on preventing sleep disturbance and delirium during high flow oxygen therapy in patients with acute respiratory failure.
Date of disclosure of the study information 2015/02/01
Last modified on 2019/11/14 09:40:29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of dexmedetomidine on preventing sleep disturbance and delirium during high flow oxygen therapy in patients with acute respiratory failure.

Acronym

Dexmedetomidine for sleep disturbance and delirium during high flow oxygen therapy

Scientific Title

Effects of dexmedetomidine on preventing sleep disturbance and delirium during high flow oxygen therapy in patients with acute respiratory failure.

Scientific Title:Acronym

Dexmedetomidine for sleep disturbance and delirium during high flow oxygen therapy

Region

Japan


Condition

Condition

Adult patients with acute respiratory failure treated with high flow oxygen therapy

Classification by specialty

Intensive care medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the effectiveness of dexmedetomidine on preventing sleep disturbance and delirium during high flow oxygen therapy in adult patients with acute respiratory failure.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

Sleep quality and quantity (total sleep time, the rate of each sleep stage: non-REM sleep stage 1-3, REM sleep) and the incidence rate of delirium.

Key secondary outcomes

successful rate of liberation from high flow oxygen therapy, the length of ICU stay, and mortality.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

No treatment

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Dexmedetomidine 0.2-0.7mcg/kg/h for nocturnal sedation

Interventions/Control_2

No sedation or sedation without dexmedetomidine during night time.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

90 years-old >

Gender

Male and Female

Key inclusion criteria

Adult patients with acute respiratory failure equipped with high flow oxygen therapy in the intensive care units.

Key exclusion criteria

Major cardiovascular disease, shock, cerebrovascular disease, known sleep apnea syndrome, mental disorder.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Jun
Middle name
Last name Oto

Organization

Tokushima University Hospital

Division name

Emergency and Critical Care Medicine

Zip code

770-8503

Address

3-18-15 Kuramoto-cho Tokushima-city Tokushima, Japan

TEL

088-633-9347

Email

joto@tokushima-u.ac.jp


Public contact

Name of contact person

1st name Jun
Middle name
Last name Oto

Organization

Tokushima University Hospital

Division name

Emergency and Critical Care Medicine

Zip code

770-8503

Address

3-18-15 Kuramoto-cho Tokushima-city Tokushima, Japan

TEL

088-633-9347

Homepage URL


Email

joto@tokushima-u.ac.jp


Sponsor or person

Institute

Tokushima University Hospital

Institute

Department

Personal name



Funding Source

Organization

Emergency and Critical Care Medicine, The University of Tokushima Graduate School

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Clinical trial center for developmental of therapeutics

Address

2-50-1 Kuramoto-cho Tokushima

Tel

088-633-9294

Email

awachiken@tokushima-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

徳島大学病院(徳島県)


Other administrative information

Date of disclosure of the study information

2015 Year 02 Month 01 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled

24

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 12 Month 01 Day

Date of IRB

2014 Year 12 Month 22 Day

Anticipated trial start date

2015 Year 01 Month 20 Day

Last follow-up date

2019 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 11 Month 10 Day

Last modified on

2019 Year 11 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018195


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name